艾昆纬（IQVIA）：2026放射性药物推动肿瘤药物研发创新白皮书（英文版）（12页）.pdf

1、White PaperRadiopharmaceuticals Are Driving Innovation in Oncology Drug DevelopmentDAVID ALSADIUS,MD,PHD,Senior Medical Director,Solid Tumor Lead,Hematology-Oncology Center of Excellence,IQVIA MICHAEL ARMSTRONG,MD,PHD,Senior Director,Medical,Hematology-Oncology Center of Excellence,IQVIA Biotech MIC

2、HAEL BRAVE,MD,Vice President,Therapeutic and Regulatory Strategy,IQVIACARSTEN HENKE,Client Partner,IQVIA AMANDA POTOCKY,Director,Clinical Project Management,Immuno-Oncology and Cell and Gene Therapy Oncology,IQVIA BiotechTable of contentsExecutive summary 3Key insights 3The evolution of radiopharmac

3、euticals 3Increased momentum for development 4A shifting regulatory landscape 5Unique operational issues 7Bringing the benefits to patients 8Conclusions 10 |3Radiation has been used to treat cancer for more than a century but comes with serious toxicities due to exposure of healthy tissue to radiati

4、on.Reducing radiation exposure of healthy tissue is a key consideration of conformal radiation therapy,which matches treatment to the biological characteristics of the tumor being treated and the patients predicted tolerance of radiation.Radioligand therapy,also known as radiopharmaceutical therapy(

5、RPT),is a novel treatment modality in oncology directed at these goals.Additionally,RPTs address the tenets of precision medicine the most specific available treatment for the most specific available diagnosis to patients by using a theranostic approach,useful for both diagnosis and treatment.Recent

6、 success in clinical trials,earlier and expanded use and an increasing repertoire of therapeutic targets are improving the potential and momentum of RPT development.In this white paper,we address regulatory and logistical challenges unique to this exciting and expanding opportunity to bring new trea